Compare AANJANEYA LIFECARE with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS TORRENT PHARMA DR. DATSONS LABS/
TORRENT PHARMA
 
P/E (TTM) x -10.9 59.8 - View Chart
P/BV x 0.2 6.3 2.6% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 DR. DATSONS LABS   TORRENT PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
TORRENT PHARMA
Mar-18
DR. DATSONS LABS/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1261,550 8.1%   
Low Rs311,144 2.7%   
Sales per share (Unadj.) Rs133.0354.7 37.5%  
Earnings per share (Unadj.) Rs0.240.1 0.4%  
Cash flow per share (Unadj.) Rs6.664.2 10.3%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs128.8273.1 47.2%  
Shares outstanding (eoy) m31.66169.22 18.7%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.63.8 15.5%   
Avg P/E ratio x516.133.6 1,535.8%  
P/CF ratio (eoy) x11.821.0 56.5%  
Price / Book Value ratio x0.64.9 12.3%  
Dividend payout %034.9 0.0%   
Avg Mkt Cap Rs m2,477227,897 1.1%   
No. of employees `000NA14.7 0.0%   
Total wages/salary Rs m5611,353 0.5%   
Avg. sales/employee Rs ThNM4,083.0-  
Avg. wages/employee Rs ThNM772.3-  
Avg. net profit/employee Rs ThNM461.3-  
INCOME DATA
Net Sales Rs m4,21160,021 7.0%  
Other income Rs m792,988 2.6%   
Total revenues Rs m4,28963,009 6.8%   
Gross profit Rs m56913,493 4.2%  
Depreciation Rs m2044,086 5.0%   
Interest Rs m4303,085 13.9%   
Profit before tax Rs m139,310 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m62,529 0.2%   
Profit after tax Rs m56,781 0.1%  
Gross profit margin %13.522.5 60.1%  
Effective tax rate %48.027.2 176.8%   
Net profit margin %0.111.3 1.0%  
BALANCE SHEET DATA
Current assets Rs m6,85252,623 13.0%   
Current liabilities Rs m6,71152,022 12.9%   
Net working cap to sales %3.31.0 334.2%  
Current ratio x1.01.0 100.9%  
Inventory Days Days161120 134.5%  
Debtors Days Days31876 417.8%  
Net fixed assets Rs m3,67385,016 4.3%   
Share capital Rs m317846 37.4%   
"Free" reserves Rs m3,76145,376 8.3%   
Net worth Rs m4,07846,222 8.8%   
Long term debt Rs m1,67141,115 4.1%   
Total assets Rs m12,633142,432 8.9%  
Interest coverage x1.04.0 25.6%   
Debt to equity ratio x0.40.9 46.1%  
Sales to assets ratio x0.30.4 79.1%   
Return on assets %3.46.9 49.7%  
Return on equity %0.114.7 0.8%  
Return on capital %7.714.2 54.1%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96414,580 6.6%   
Fx outflow Rs m6073,600 16.9%   
Net fx Rs m35710,980 3.3%   
CASH FLOW
From Operations Rs m1,3458,942 15.0%  
From Investments Rs m-2,256-47,070 4.8%  
From Financial Activity Rs m-1,20034,174 -3.5%  
Net Cashflow Rs m-2,111-3,655 57.7%  

Share Holding

Indian Promoters % 4.5 71.5 6.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 7.0 -  
FIIs % 1.4 12.6 10.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 8.8 1,069.3%  
Shareholders   20,807 26,511 78.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare DR. DATSONS LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 5-YR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS